Ian M Catlett

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 4

Top Topics

Tyrosine Kinase

Structural Basis

Top Venues

Dermatology and therapy

Clinical and translational science

British journal of clinical pharmacology

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Ian M Catlett, Lu Gao, Yanhua Hu, Subhashis Banerjee, James G Krueger
Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial. Dermatology and therapy (2024)
Ian M Catlett, Urvi Aras, Lars Hansen, Yali Liu, Di Bei, Ihab G Girgis, Bindu Murthy
First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clinical and translational science (2022)
James R Burke, Lihong Cheng, Kathleen M Gillooly, Joann Strnad, Adriana Zupa-Fernandez, Ian M Catlett, Yifan Zhang, Elizabeth M Heimrich, Kim W McIntyre, Mark D Cunningham, Julie A Carman, Xiadi Zhou, Dana Banas, Charu Chaudhry, Sha Li, Celia D'Arienzo, Anjaneya Chimalakonda, XiaoXia Yang, Jenny H Xie, Jian Pang, Qihong Zhao, Shawn M Rose, Jinwen Huang, Ryan M Moslin, Stephen T Wrobleski, David S Weinstein, Luisa M Salter-Cid
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Science translational medicine 11 (502) (2020)
Ian M Catlett, Miroslawa Nowak, Sudeep Kundu, Naiyu Zheng, Ang Liu, Bing He, Ihab G Girgis, Dennis M Grasela
Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants. British journal of clinical pharmacology 86 (9) (2020)